MedPath

Randomized clinical study to evaluate utility of response adapted treatment in patients with newly diagnosed multiple myeloma

Phase 3
Conditions
Health Condition 1: C900- Multiple myeloma
Registration Number
CTRI/2021/11/037702
Lead Sponsor
Intramural grant of Tata Memorial Center Mumbai
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.patient with histologically proven PCNSL

2. Received methotrexate based induction therapy

3. Radio logical consolidation therapy after achieving CR

5.Age >18 years

6.PS >2 after the completion of consolidation therpy

7.Adequate bone marrow function with absolute leukocytes >2000mm3,neutrophil count ANC >1000/mm3.haemoglobin >8g/dl and platelets >100000/mm3

8.Adecute liver function with serum SGOT/AST or SGPT/ALT <3.0Xupper limit of Normal ULN;bilirubin <1.5XLNS

9.Creatinineclearance >30ml/min.Patients with calculated ceratine cleearance between 30 and 60 ml/min lenalidomide dose will be adjusted as follows(10 mg oncedalily)

10.Able to take aspirin(75mg) daily as prophylactic anticoagulant

11.Able to understand the teratogenicity

12.Men and women of child bearing age should agree to use reliable contraception

13. Neuropathy of >grade 2 severity

14.Able to understand and sign inform consent

Exclusion Criteria

Diagnosis of sleep apnea or any other chronic respiratory disease

• Any acute or chronic condition that would limit the ability of the patient to participate in the study

• Refusal to give informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Phase 2: MRd negativity rates at 1 year from randomization <br/ ><br>Phase 2: PFS rated at 2 years from RandomizationTimepoint: Phase 2: MRd negativity rates at 1 year from randomization <br/ ><br>Phase 2: PFS rated at 2 years from Randomization
Secondary Outcome Measures
NameTimeMethod
Grade 3 or more SAE of MRD guided therapy.Timepoint: 1 year;Overall survival <br/ ><br>Timepoint: 2 years
© Copyright 2025. All Rights Reserved by MedPath